[go: up one dir, main page]

WO2006116688A3 - Agonistes et antagonistes de mif et leurs utilisations therapeutiques - Google Patents

Agonistes et antagonistes de mif et leurs utilisations therapeutiques Download PDF

Info

Publication number
WO2006116688A3
WO2006116688A3 PCT/US2006/016254 US2006016254W WO2006116688A3 WO 2006116688 A3 WO2006116688 A3 WO 2006116688A3 US 2006016254 W US2006016254 W US 2006016254W WO 2006116688 A3 WO2006116688 A3 WO 2006116688A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
disease associated
mif expression
antagonists
low mif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/016254
Other languages
English (en)
Other versions
WO2006116688A2 (fr
Inventor
Richard Bucala
Lin Leng
Sarah Doernberg
Michael Bukrinsky
Seamas Donnelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to US11/919,307 priority Critical patent/US20100143379A1/en
Publication of WO2006116688A2 publication Critical patent/WO2006116688A2/fr
Publication of WO2006116688A3 publication Critical patent/WO2006116688A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes et des compositions pour sélectionner un patient à traiter à l'aide d'un agoniste ou d'un antagoniste d'un facteur d'inhibition de migration de macrophages (MIF), pour identifier un patient présentant un risque de développer une maladie associée à une expression MIF élevée ou faible, pour prédire la gravité d'une maladie associée à une expression MIF élevée ou faible chez un patient, et pour prédire si un patient est susceptible de développer une maladie associée à une expression MIF élevée ou faible. L'invention concerne également de nouvelles méthodes pour diagnostiquer un patient présentant une maladie associée à une expression MIF élevée ou faible. L'invention concerne encore des méthodes pour traiter un patient présentant une maladie ou un trouble associé à une expression MIF élevée ou faible.
PCT/US2006/016254 2005-04-26 2006-04-26 Agonistes et antagonistes de mif et leurs utilisations therapeutiques Ceased WO2006116688A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/919,307 US20100143379A1 (en) 2005-04-26 2006-04-26 Mif agonists and antagonist and therapeutic uses thereof

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US67530305P 2005-04-26 2005-04-26
US60/675303 2005-04-26
US68553305P 2005-05-27 2005-05-27
US60/685533 2005-05-27
US68748105P 2005-06-02 2005-06-02
US60/687481 2005-06-02
US68886505P 2005-06-08 2005-06-08
US60/688865 2005-06-08
US69883305P 2005-07-12 2005-07-12
US60/698833 2005-07-12
US72504905P 2005-10-07 2005-10-07
US60/725049 2005-10-07
US73279705P 2005-11-02 2005-11-02
US60/732797 2005-11-02

Publications (2)

Publication Number Publication Date
WO2006116688A2 WO2006116688A2 (fr) 2006-11-02
WO2006116688A3 true WO2006116688A3 (fr) 2007-07-26

Family

ID=37215552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/016254 Ceased WO2006116688A2 (fr) 2005-04-26 2006-04-26 Agonistes et antagonistes de mif et leurs utilisations therapeutiques

Country Status (1)

Country Link
WO (1) WO2006116688A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2203558T3 (en) 2007-10-18 2016-06-27 Cell Signaling Technology Inc TRANSLOCATION AND mutant ROS kinase IN HUMAN NON-small cell lung carcinoma
EP2198879A1 (fr) 2008-12-11 2010-06-23 Institut Curie Agent modulateur de CD74 pour la régulation de la migration de cellules dendritiques et dispositif pour l'étude de la capacité de motilité d'une cellule
US8367350B2 (en) 2009-04-29 2013-02-05 Morehouse School Of Medicine Compositions and methods for diagnosis, prognosis and management of malaria
JP2014526886A (ja) 2011-07-15 2014-10-09 モルフォシス・アー・ゲー マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
US20240024335A1 (en) * 2020-12-11 2024-01-25 Sanquin IP B.V. Treatment and prevention of anaemia of inflammation
CN115252636A (zh) * 2022-06-15 2022-11-01 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种寡聚脱氧核苷酸及其在制备抗肿瘤药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083813A1 (fr) * 2000-05-02 2001-11-08 Centre National De La Recherche Scientifique Identification de marqueurs genetiques
WO2002007720A1 (fr) * 2000-07-26 2002-01-31 The Picower Institute For Medical Research Composes ayant une activite d'antagoniste de mif
US20030099653A1 (en) * 1993-05-17 2003-05-29 Bucala Richard J. Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
WO2003060468A2 (fr) * 2001-12-21 2003-07-24 Cytokine Pharmasciences, Inc. Polymorphisme promoteur du facteur d'inhibition des macrophages dans les maladies inflammatoires
WO2005020919A2 (fr) * 2003-08-29 2005-03-10 Cytokine Pharmasciences, Inc. Methode de traitement et dosage biologique faisant appel a un facteur d'inhibition de la migration des macrophages (mif) utilise comme facteur depresseur du myocarde d'origine cardiaque

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099653A1 (en) * 1993-05-17 2003-05-29 Bucala Richard J. Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
WO2001083813A1 (fr) * 2000-05-02 2001-11-08 Centre National De La Recherche Scientifique Identification de marqueurs genetiques
WO2002007720A1 (fr) * 2000-07-26 2002-01-31 The Picower Institute For Medical Research Composes ayant une activite d'antagoniste de mif
WO2003060468A2 (fr) * 2001-12-21 2003-07-24 Cytokine Pharmasciences, Inc. Polymorphisme promoteur du facteur d'inhibition des macrophages dans les maladies inflammatoires
WO2005020919A2 (fr) * 2003-08-29 2005-03-10 Cytokine Pharmasciences, Inc. Methode de traitement et dosage biologique faisant appel a un facteur d'inhibition de la migration des macrophages (mif) utilise comme facteur depresseur du myocarde d'origine cardiaque

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BAUGH & DONNELLY: "Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation.", THE JOURNAL OF ENDOCRINOLOGY. OCT 2003, vol. 179, no. 1, October 2003 (2003-10-01), pages 15 - 23, XP002408028, ISSN: 0022-0795 *
BAUGH J A ET AL: "A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis.", GENES AND IMMUNITY. MAY 2002, vol. 3, no. 3, May 2002 (2002-05-01), pages 170 - 176, XP008039746, ISSN: 1466-4879 *
DE BENEDETTI FABRIZIO ET AL: "FUNCTIONAL AND PROGNOSTIC RELEVANCE OF THE -173 POLYMORPHISM OF THE MACROPHAGE MIGRATION INHIBITORY FACTOR GENE IN SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 48, no. 5, May 2003 (2003-05-01), pages 1398 - 1407, XP008071511, ISSN: 0004-3591 *
DONN RACHELLE P ET AL: "Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY. SEP 2004, vol. 123, no. 3, September 2004 (2004-09-01), pages 484 - 487, XP002408026, ISSN: 0022-202X *
MORAND ERIC F ET AL: "Macrophage Migration Inhibitory Factor", ARTHRITIS AND RHEUMATISM. FEB 2003, vol. 48, no. 2, February 2003 (2003-02-01), pages 291 - 299, XP002408029, ISSN: 0004-3591 *
RENNER ET AL: "Macrophage Migration Inhibitory Factor: Gene polymorphisms and susceptibility to inflammatory disease.", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, US, vol. 41, 15 November 2005 (2005-11-15), pages S513 - S519, XP008071560, ISSN: 1058-4838 *
SHI ET AL: "Technologies for detecting genetic polymorphisms in pharmacogenomics", MOLECULAR DIAGNOSIS, NAPERVILLE, IL, US, vol. 4, no. 4, December 1999 (1999-12-01), pages 343 - 351, XP005533504, ISSN: 1084-8592 *
SHI M W: "TECHNOLOGIES FOR INDIVIDUAL GENOTYPING: DETECTION OF GENETIC POLYMORHPISMS IN DRUG TARGETS AND DISEASE GENES", AMERICAN JOURNAL OF PHARMACOGENOMICS, XX, XX, vol. 2, no. 3, 2002, pages 197 - 205, XP009065150, ISSN: 1175-2203 *
ZHONG XIAO-BO ET AL: "Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies.", NUCLEIC ACIDS RESEARCH. 2005, vol. 33, no. 13, 2005, pages e121, XP002408027, ISSN: 1362-4962 *

Also Published As

Publication number Publication date
WO2006116688A2 (fr) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2008070137A3 (fr) Marqueurs pharmacodynamiques alpha-induit d'interféron
WO2007044860A3 (fr) Marqueurs associes au diabete et procedes d'utilisation de ceux-ci
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2008106429A3 (fr) Procédés et compositions pour le traitement de l'insuffisance cardiaque et d'autres troubles
WO2009101059A3 (fr) Procédés d'utilisation d'antagonistes de la cadhérine 11 (cdh11)
WO2007041245A3 (fr) Marqueurs biologiques de la sclerose en plaques et methodes d'utilisation de ceux-ci
WO2007013575A3 (fr) Procede pour le diagnostic et le traitement d'hypernephrome
WO2009055001A3 (fr) Procédés pour le traitement du vieillissement et procédés de dépistage des agents contribuant à celui-ci
WO2005023291A3 (fr) Utilisation d'agonistes de glp-i dans le traitement de patients souffrant de diabete de type i
WO2006116688A3 (fr) Agonistes et antagonistes de mif et leurs utilisations therapeutiques
WO2006059252A3 (fr) Procedes et compositions fluorees pour le traitement de maladies associees aux amyloides
WO2004045376A3 (fr) Methodes de criblage permettant d'identifier des traitements contre une maladie auto-immune
WO2007044622A8 (fr) Utilisation de mif et d'agonistes de la voie mif
MXPA05008805A (es) Metodo de tratamiento de enfermedad utilizando un antagonista de receptor de adenosina a1.
Hartman et al. RNA mis‐splicing in children with congenital myotonic dystrophy is associated with physical function
EP2539709A4 (fr) Altérations propres à la maladie d'alzheimer des niveaux de protéine kinase c epsilon (pkc-epsilon)
WO2007015113A3 (fr) Nouveaux isoformes de proteines et leurs utilisations
WO2006085121A3 (fr) Biomarqueurs et leurs utilisations
WO2008008487A3 (fr) Profil d'expression génique pour identification, surveillance et traitement de la sclérose en plaques
ATE402739T1 (de) Behandlung von entzündungen
WO2005124358A3 (fr) Diagnostic et traitement de maladies associees a siglec-6
WO2004048550A3 (fr) Proteines associees a une reponse immune
WO2005000099A3 (fr) Domaines de facteurs sanguins (bfd)
WO2004048529A3 (fr) Proteines de matrice extracellulaire et d'adhesion cellulaire
BRPI0515727A (pt) biomarcador para insuficiência cardìaca

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06751775

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11919307

Country of ref document: US